Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 2/20 | 0.39 |
| ▸ | BLM | P54132 | 2/20 | 0.39 |
| ▸ | TDP2 | O95551 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23056136 | 0.84 | ALDH1A1 (0.48) | MAPTKDM4EHIF1AHSD17B10KMT2A | |
| SCHEMBL13836388 | 0.78 | KMT2A (0.48) | MAPTKMT2AMEN1L3MBTL1MAPK1 | |
| SCHEMBL20282082 | 0.76 | MAPT (0.55) | MAPTKDM4EHIF1AHSD17B10KMT2A | |
| SCHEMBL9533749 | 0.74 | MAPT (0.58) | MAPTKDM4EHIF1AHSD17B10KMT2A | |
| SCHEMBL1820230 | 0.74 | KMT2A (0.46) | MAPTKMT2AMEN1L3MBTL1MAPK1 | |
| SCHEMBL1172982 | 0.74 | KMT2A (0.46) | MAPTKMT2AMEN1L3MBTL1MAPK1 | |
| SCHEMBL3893783 | 0.74 | KMT2A (0.46) | MAPTKDM4EHSD17B10KMT2AMEN1 | |
| SCHEMBL57595 | 0.74 | KMT2A (0.46) | MAPTKMT2AMEN1L3MBTL1MAPK1 | |
| SCHEMBL5543675 | 0.74 | ACHE (0.54) | MAPTKMT2AMEN1L3MBTL1MAPK1 | |
| SCHEMBL10305615 | 0.74 | KMT2A (0.46) | MAPTKMT2AMEN1L3MBTL1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116535340-A | Substituted N-aryl-1-naphthylamine compound, preparation method and pharmaceutical application thereof | 中国医学科学院药物研究所 | 2023-08-04 | — | — | CN | disclosed |
| EP-3782990-A1 | MOFEZOLAC DERIVATIVES AS MULTI-FUNCTIONS SELECTIVE COX-1 INHIBITORS | Università degli Studi di Bari "Aldo Moro" (IT) | 2021-02-24 | — | — | EP | disclosed |
| WO-2017187352-A1 | MOFEZOLAC DERIVATIVES AS MULTI-FUNCTIONS SELECTIVE COX-1 INHIBITORS | UNIVERSITA' DEGLI STUDI DI BARI "ALDO MORO" (IT) | 2017-11-02 | — | — | WO | disclosed |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| WO-2017089952-A1 | DEGRADABLE CONJUGATED POLYMERS | The Board of Trustees of the Leland Stanford Junior University Office of the General Counsel (US) | 2017-06-01 | — | — | WO | disclosed |
| US-9630947-B2 | Therapeutic compounds and related methods of use | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-04-25 | — | — | US | disclosed |
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | GALENEA CORPORATION | 2015-10-29 | — | — | US | disclosed |
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | GALENEA CORPORATION | 2015-10-29 | — | — | US | disclosed |
| US-8563714-B2 | Bridged spiro [2.4] heptane derivatives as ALX receptor and/or FPRL2 agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-10-22 | — | — | US | disclosed |
| US-7034047-B2 | Triazole derivative | ASTELLAS PHARMA, INC. (JP) | 2006-04-25 | — | — | US | disclosed |
| US-20060025461-A1 | Triazole derivative | ASTELLAS PHARMA INC. | 2006-02-02 | — | — | US | disclosed |
| WO-2006002284-A1 | UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2006-01-05 | — | — | WO | disclosed |
| US-20050282818-A1 | Ubiquitin ligase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2005-12-22 | — | — | US | disclosed |
| US-20040214818-A1 | Triazole derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD., MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG | 2004-10-28 | — | — | US | disclosed |
| US-20030216385-A1 | Triazole derivatives | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2003-11-20 | — | — | US | disclosed |
| EP-1293503-A1 | TRIAZOLE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-03-19 | — | — | EP | disclosed |
| EP-0733626-B1 | N-(Benzofuranazyl)-arylsulphonamides and their analogues useful as endothelin-receptor-antagonists | MERCK PATENT GMBH (DE) | 1999-01-13 | — | — | EP | disclosed |
| US-5726194-A | Endothelin receptor antagonists | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1998-03-10 | — | — | US | disclosed |
| EP-0733626-A1 | N-(Benzofuranazyl)-arylsulphonamides and their analogues useful as endothelin-receptor-antagonists | MERCK PATENT GmbH (DE) | 1996-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214818-A1 | Triazole derivative | SLC18A3, SLC6A3, SLC18A2 | MAPT 364/4885KDM4E 3994/4885HIF1A 3471/4885 |
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PTPRG, PPP2CA | MAPT 519/4885KDM4E 1215/4885HIF1A 4252/4885 |
| US-20030216385-A1 | Triazole derivatives | SLC18A3, SLC18A2, SLC6A3 | MAPT 362/4885KDM4E 4058/4885HIF1A 3482/4885 |
| US-20050282818-A1 | Ubiquitin ligase inhibitors | NEDD4, TRAF6, XIAP | MAPT 1681/4885KDM4E 536/4885HIF1A 1926/4885 |
| US-20060025461-A1 | Triazole derivative | SLC18A3, SLC6A3, SLC18A2 | MAPT 364/4885KDM4E 3994/4885HIF1A 3471/4885 |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PTPRG, PPP2CA | MAPT 519/4885KDM4E 1215/4885HIF1A 4252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.